Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab + pomalidomide + dexamethasone versus standard of care in relapsed/refractory multiple myeloma
ChiCTR2600131523Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cevostamab in multiple myeloma (MM) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: MRD-negative complete response rate at 9 months and Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600131523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131523.